, Tracking Stock Market Picks
Enter Symbol:
Celldex Therapeutics, Inc. (CLDX) [hlAlert]

Strong Buy
up 172.25 %

Celldex Therapeutics Inc (AVAN) rated Strong Buy with price target $15 by WBB Securities

Posted on: Wednesday,  May 5, 2010  9:25 AM ET by WBB Securities

WBB Securities rated Strong Buy Celldex Therapeutics, Inc. (NASDAQ: CLDX) on 05/05/2010. Previously WBB Securities rated Strong Buy Celldex Therapeutics, Inc. (NASDAQ: CLDX)
on 09/29/2009., when the stock price was $5.55. Since then, Celldex Therapeutics, Inc. has gained 172.25% as of 01/25/2016's recent price of $15.11.
If you would have followed the previous WBB Securities's recommendation on CLDX, you would have gained 172.25% of your investment in 2309 days.

Celldex Therapeutics, Inc. (Celldex) is a biopharmaceutical company, which applies its Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. The Company?s immunotherapy platform includes a portfolio of monoclonal antibodies, antibody-targeted vaccines, antibody-drug conjugates and immunomodulators to create disease-specific drug candidates. Its collaborations include the commercialization of an oral human rotavirus vaccine and the development of oncology and infectious disease vaccines. On October 1, 2009, Celldex acquired CuraGen Corporation.

Research from WBB Securities provides investment professionals with up-to-date, in-depth, accurate and insightful reporting of companies that specialize in biotechnology, medical devices and healthcare. Our goal is to provide independent, straight-forward and up-to-date research so you can make educated decisions about your investments.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/5/2010 9:25 AM Buy
7.70 15.00
as of 12/31/2010
1 Week down  -9.66 %
1 Month down  -9.87 %
3 Months down  -6.50 %
1 YTD down  -19.91 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/29/2009 5:25 PM Buy
5.55 10.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy